Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 215-224

  Gálvez, Rafael ^a   Ribera, Victoria ^b   González Escalada, José Ramón ^c   Souto, Alicia ^d   Cánovas, María Luz ^d   Castro, Andrés ^d   Herrero, Begoña ^e   Maqueda, María de los Ángeles ^e   Castilforte, Matilde ^f   Marco Martínez, José Javier ^g   Pérez, Concepción ^h   Vicente Fatela, Lorenza ⁱ   Consuelo Nieto, M D ^j   Orduña, Maria José ^k   Padrol, Anna ^l   Reig, Enrique ^m   Carballido, Joaquín ^m   Cózar, José Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Hospital Cristal Pinor   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^k HOSPITAL XERAL CALDE   (Spain)

^l HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^m HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

Bone metastasis; Pain; Prostate cancer; Zoledronic acid

Indexed keywords

EID: 84855589238     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S2314     Document Type: Article

References (34)

1. Adami S., Zamberlan N. 1996. Adverse effects of bisphosphonates. A comparative review. Drug Safety, 14:158-70.
2. Averbuch S. 1993. New bisphosphonates in the treatment of bone metastasis. Cancer, 72(Suppl):3443-52.
3. Berenson J.R. 2005. Recommendations for zoledronic acid treatment of patients with bone metastasis. Oncologist, 10:52-62.
4. Berruti A., Dogliotti L, Tucci M, et al. 2001. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol, 166:2023-31.
5. Boissier S., Ferreras M, Peyruchaud O, et al. 2000. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasis. Cancer Res, 60:2949-54.
6. Bruera E. Organizing palliative care. Cancer Strategies for the New Millennium [online]. WHO publications. URL: http:/www.who.int/ ncd/cancer/publications/abstracts/abs9810 22.html
7. Cherny N. I, Portenoy RK. 1994. Cancer pain. Principles of assesment and syndromes. In: Wall PD, Melzack R (eds). Texbook of pain. 3rd edition. Edinburgh: Churchill Livingstone. pp. 787-823.
8. Clamp A., Danson S, Nguyen H, et al. 2004. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol, 5:607-16.
9. Clarke N. W, McClure J, George NJ. 1991. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol, 68:74-80.
10. Coleman R.E. 1991. Bisphosphonate treatment of bone metastasis and hypercalcemia of malignancy. Oncology, 5:55-60.
11. Coleman R.E. 2000. Optimising treatment of bone metastasis by Aredia™ and Zometa™. Breast Cancer, 7:361-9.
12. Coleman R.E. 2001. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 27:165-76.
13. Cózar Olmo JM, Gálvez Mateos R, Tallada Buñuel M. 1999. Modalidades terapéuticas en el dolor óseo del cáncer de próstata. Actualidad en Urología. Barcelona. Redacción Médica.
14. Daniell H.W. 1997. Osteoporosis after orchiectomy for prostate cancer. J Urol, 157: 439-44.
15. Dreicer R. 1997. Metastatic prostate cancer: assessment of response to systemic therapy. Semin Urol Oncol, 15:28-32.
16. Gálvez R. 1998. Tratamiento del dolor óseo metastásico en el cáncer de próstata. Urol Integr Invest, 3:321-9.
17. Garnero P., Buchs N, Zekri J, et al. 2000. Markers of bone turnover for the management of patients with bone metastasis from prostate cancer. Br J Cancer, 82:858-64.
18. Levy M.H. 1993. Medical management of cancer pain. In: Warfield CA (ed). Principles, practice of pain management. New Cork: McGraw Hill. pp. 235-50.
19. Major P. P, Lipton A, Berenson J, et al. 2000. Oral bisphosphonates: A review of clinical use in patients with bone metastasis. Cancer, 88:6-14.
20. Oh W.K. 2000. Chemotherapy for patients with advanced prostate carcinoma. Cancer, 8:3015-21.
21. Papapoulos S. E, Handy NA, Van der Pluijm G. 2000. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer, 88(Suppl):3047-53.
22. Payne R. 1993. Pain management in the patient with prostate cancer. Cancer, 71(Suppl):1131-7.
23. Rhiner M., Kedziera P. 1999. Managing breakthrough cancer pain: a new approach. Home Health Nurse, 17(Suppl 1-12):13-5.
24. Rogers M. J, Watts DJ, Russell RGG. 1997. Overview of bisphosphonates. Cancer, 80:1652-7.
25. Saad F., Gleason DM, Murria R, et al. 2002. and Zoledronic Acid Prostate Cancer Study Group. Randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastasic prostate carcinoma. J Natl Cancer Inst, 94:1458-68.
26. Saad F., Gleason DM, Murria R, et al. 2002. and Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst, 96:879-82.
27. Scher H. 2003. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer, 97:758-71.
28. Schmeler K., Bastin K. 1996. Strontium 89 for syntomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hosp J, 11:1-10.
29. Small E. J, Seaman JJ, Petrone S, et al. 2003. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Clin Oncol, 21:4277-84.
30. Smith M. R, McGovern FJ, Zietman AL, et al. 2001. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345:948-55.
31. Tassone P., Forciniti S, Galea E, et al. 2000. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia, 14:841-4.
32. Townsend M. F, Sanders WH, Northway RO, et al. 1997. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer, 79:545-50.
33. Warrel R.P. 1992. Etiology and current management of cancer-related hypercalcemia. Oncology, 6:37-43.
34. Zojer N., Keck AV, Pecherstorfer M. 1999. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf, 21:389-406.